Holy Stone Healthcare Co., Ltd. (4194) Stock Price & Analysis
4194 Stock Chart & Stats
- Day’s Range
- TWD 5.80 - TWD 6.14
- 52-Week Range
- TWD 5.80 - TWD 10.05
- Previous Close
- TWD 6.31
- Volume
- N/A
- Average Volume (3M)
- 129.20K
- Market Cap
- TWD 890.44M
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- TWD 79.42M
- Total Debt (Recent Filing)
- TWD 11.07M
- Price to Earnings (P/E)
- ―
- Beta
- 0.43
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
4194 FAQ
What was Holy Stone Healthcare Co., Ltd.’s price range in the past 12 months?
What is Holy Stone Healthcare Co., Ltd.’s market cap?
When is Holy Stone Healthcare Co., Ltd.’s upcoming earnings report date?
Is Holy Stone Healthcare Co., Ltd. overvalued?
Does Holy Stone Healthcare Co., Ltd. pay dividends?
What is Holy Stone Healthcare Co., Ltd.’s EPS estimate?
How many shares outstanding does Holy Stone Healthcare Co., Ltd. have?
Which hedge fund is a major shareholder of Holy Stone Healthcare Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Holy Stone Healthcare Co., Ltd.
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer’s disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Raymond Yang
- Employees
- 309
- Website
- www.hshc.com.tw
- Address
- No. 88, Neihu Rd., Taipei, TPE, 11493, TW
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |
